Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Xu, Qingyong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Towards a Dynamic Understanding of Cadherin-Based Mechanobiology - Hoffman, Brenton D. ELSEVIER, 2015, official journal of the American Society for Histocompatibility and Immunogenetics (ASHI), Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:80 ; year:2019 ; number:7 ; pages:487-492 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.humimm.2019.03.015 |
|---|
| Katalog-ID: |
ELV047233613 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047233613 | ||
| 003 | DE-627 | ||
| 005 | 20230626015230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.humimm.2019.03.015 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000667.pica |
| 035 | |a (DE-627)ELV047233613 | ||
| 035 | |a (ELSEVIER)S0198-8859(18)31099-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Xu, Qingyong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. | ||
| 520 | |a Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. | ||
| 650 | 7 | |a FCXM |2 Elsevier | |
| 650 | 7 | |a CDC |2 Elsevier | |
| 650 | 7 | |a DSA |2 Elsevier | |
| 650 | 7 | |a PD |2 Elsevier | |
| 650 | 7 | |a PE |2 Elsevier | |
| 650 | 7 | |a XM |2 Elsevier | |
| 650 | 7 | |a AMR |2 Elsevier | |
| 650 | 7 | |a HLA |2 Elsevier | |
| 650 | 7 | |a HD |2 Elsevier | |
| 650 | 7 | |a PRA |2 Elsevier | |
| 700 | 1 | |a House, Andrew A. |4 oth | |
| 700 | 1 | |a Leckie, Steve |4 oth | |
| 700 | 1 | |a Gunaratnam, Lakshman |4 oth | |
| 700 | 1 | |a Luke, Patrick P. |4 oth | |
| 700 | 1 | |a Jevnikar, Anthony M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Hoffman, Brenton D. ELSEVIER |t Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |d 2015 |d official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) |g Amsterdam [u.a.] |w (DE-627)ELV000456578 |
| 773 | 1 | 8 | |g volume:80 |g year:2019 |g number:7 |g pages:487-492 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.humimm.2019.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2019 |e 7 |h 487-492 |g 6 | ||
| author_variant |
q x qx |
|---|---|
| matchkey_str |
xuqingyonghouseandrewaleckiestevegunarat:2019----:ainsihmuooiadsaeooprtnadayiaerntfleoi |
| hierarchy_sort_str |
2019transfer abstract |
| publishDate |
2019 |
| allfields |
10.1016/j.humimm.2019.03.015 doi GBV00000000000667.pica (DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid Xu, Qingyong verfasserin aut Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch 2019transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier House, Andrew A. oth Leckie, Steve oth Gunaratnam, Lakshman oth Luke, Patrick P. oth Jevnikar, Anthony M. oth Enthalten in Elsevier Science Hoffman, Brenton D. ELSEVIER Towards a Dynamic Understanding of Cadherin-Based Mechanobiology 2015 official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) Amsterdam [u.a.] (DE-627)ELV000456578 volume:80 year:2019 number:7 pages:487-492 extent:6 https://doi.org/10.1016/j.humimm.2019.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 80 2019 7 487-492 6 |
| spelling |
10.1016/j.humimm.2019.03.015 doi GBV00000000000667.pica (DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid Xu, Qingyong verfasserin aut Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch 2019transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier House, Andrew A. oth Leckie, Steve oth Gunaratnam, Lakshman oth Luke, Patrick P. oth Jevnikar, Anthony M. oth Enthalten in Elsevier Science Hoffman, Brenton D. ELSEVIER Towards a Dynamic Understanding of Cadherin-Based Mechanobiology 2015 official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) Amsterdam [u.a.] (DE-627)ELV000456578 volume:80 year:2019 number:7 pages:487-492 extent:6 https://doi.org/10.1016/j.humimm.2019.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 80 2019 7 487-492 6 |
| allfields_unstemmed |
10.1016/j.humimm.2019.03.015 doi GBV00000000000667.pica (DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid Xu, Qingyong verfasserin aut Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch 2019transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier House, Andrew A. oth Leckie, Steve oth Gunaratnam, Lakshman oth Luke, Patrick P. oth Jevnikar, Anthony M. oth Enthalten in Elsevier Science Hoffman, Brenton D. ELSEVIER Towards a Dynamic Understanding of Cadherin-Based Mechanobiology 2015 official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) Amsterdam [u.a.] (DE-627)ELV000456578 volume:80 year:2019 number:7 pages:487-492 extent:6 https://doi.org/10.1016/j.humimm.2019.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 80 2019 7 487-492 6 |
| allfieldsGer |
10.1016/j.humimm.2019.03.015 doi GBV00000000000667.pica (DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid Xu, Qingyong verfasserin aut Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch 2019transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier House, Andrew A. oth Leckie, Steve oth Gunaratnam, Lakshman oth Luke, Patrick P. oth Jevnikar, Anthony M. oth Enthalten in Elsevier Science Hoffman, Brenton D. ELSEVIER Towards a Dynamic Understanding of Cadherin-Based Mechanobiology 2015 official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) Amsterdam [u.a.] (DE-627)ELV000456578 volume:80 year:2019 number:7 pages:487-492 extent:6 https://doi.org/10.1016/j.humimm.2019.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 80 2019 7 487-492 6 |
| allfieldsSound |
10.1016/j.humimm.2019.03.015 doi GBV00000000000667.pica (DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid Xu, Qingyong verfasserin aut Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch 2019transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier House, Andrew A. oth Leckie, Steve oth Gunaratnam, Lakshman oth Luke, Patrick P. oth Jevnikar, Anthony M. oth Enthalten in Elsevier Science Hoffman, Brenton D. ELSEVIER Towards a Dynamic Understanding of Cadherin-Based Mechanobiology 2015 official journal of the American Society for Histocompatibility and Immunogenetics (ASHI) Amsterdam [u.a.] (DE-627)ELV000456578 volume:80 year:2019 number:7 pages:487-492 extent:6 https://doi.org/10.1016/j.humimm.2019.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 80 2019 7 487-492 6 |
| language |
English |
| source |
Enthalten in Towards a Dynamic Understanding of Cadherin-Based Mechanobiology Amsterdam [u.a.] volume:80 year:2019 number:7 pages:487-492 extent:6 |
| sourceStr |
Enthalten in Towards a Dynamic Understanding of Cadherin-Based Mechanobiology Amsterdam [u.a.] volume:80 year:2019 number:7 pages:487-492 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
FCXM CDC DSA PD PE XM AMR HLA HD PRA |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |
| authorswithroles_txt_mv |
Xu, Qingyong @@aut@@ House, Andrew A. @@oth@@ Leckie, Steve @@oth@@ Gunaratnam, Lakshman @@oth@@ Luke, Patrick P. @@oth@@ Jevnikar, Anthony M. @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000456578 |
| dewey-sort |
3570 |
| id |
ELV047233613 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047233613</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.humimm.2019.03.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000667.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047233613</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0198-8859(18)31099-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xu, Qingyong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FCXM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DSA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">XM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HLA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PRA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">House, Andrew A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leckie, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunaratnam, Lakshman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luke, Patrick P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jevnikar, Anthony M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hoffman, Brenton D. ELSEVIER</subfield><subfield code="t">Towards a Dynamic Understanding of Cadherin-Based Mechanobiology</subfield><subfield code="d">2015</subfield><subfield code="d">official journal of the American Society for Histocompatibility and Immunogenetics (ASHI)</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000456578</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:487-492</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.humimm.2019.03.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2019</subfield><subfield code="e">7</subfield><subfield code="h">487-492</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| author |
Xu, Qingyong |
| spellingShingle |
Xu, Qingyong ddc 570 fid BIODIV Elsevier FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| authorStr |
Xu, Qingyong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000456578 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ BIODIV DE-30 fid Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA Elsevier |
| topic |
ddc 570 fid BIODIV Elsevier FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA |
| topic_unstemmed |
ddc 570 fid BIODIV Elsevier FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA |
| topic_browse |
ddc 570 fid BIODIV Elsevier FCXM Elsevier CDC Elsevier DSA Elsevier PD Elsevier PE Elsevier XM Elsevier AMR Elsevier HLA Elsevier HD Elsevier PRA |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a a h aa aah s l sl l g lg p p l pp ppl a m j am amj |
| hierarchy_parent_title |
Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |
| hierarchy_parent_id |
ELV000456578 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000456578 |
| title |
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| ctrlnum |
(DE-627)ELV047233613 (ELSEVIER)S0198-8859(18)31099-1 |
| title_full |
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| author_sort |
Xu, Qingyong |
| journal |
Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |
| journalStr |
Towards a Dynamic Understanding of Cadherin-Based Mechanobiology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
487 |
| author_browse |
Xu, Qingyong |
| container_volume |
80 |
| physical |
6 |
| class |
570 VZ BIODIV DE-30 fid |
| format_se |
Elektronische Aufsätze |
| author-letter |
Xu, Qingyong |
| doi_str_mv |
10.1016/j.humimm.2019.03.015 |
| dewey-full |
570 |
| title_sort |
patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| title_auth |
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| abstract |
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. |
| abstractGer |
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. |
| abstract_unstemmed |
Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
7 |
| title_short |
Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch |
| url |
https://doi.org/10.1016/j.humimm.2019.03.015 |
| remote_bool |
true |
| author2 |
House, Andrew A. Leckie, Steve Gunaratnam, Lakshman Luke, Patrick P. Jevnikar, Anthony M. |
| author2Str |
House, Andrew A. Leckie, Steve Gunaratnam, Lakshman Luke, Patrick P. Jevnikar, Anthony M. |
| ppnlink |
ELV000456578 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.humimm.2019.03.015 |
| up_date |
2024-07-06T22:20:03.310Z |
| _version_ |
1803869910006235136 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047233613</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015230.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.humimm.2019.03.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000667.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047233613</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0198-8859(18)31099-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xu, Qingyong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n = 480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered ‘immunological’ (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR = 3.36, p = 0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n = 321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR = 4.79, p = 0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR = 3.27, p = 0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">FCXM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CDC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DSA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PE</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">XM</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AMR</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HLA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">PRA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">House, Andrew A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leckie, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gunaratnam, Lakshman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luke, Patrick P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jevnikar, Anthony M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hoffman, Brenton D. ELSEVIER</subfield><subfield code="t">Towards a Dynamic Understanding of Cadherin-Based Mechanobiology</subfield><subfield code="d">2015</subfield><subfield code="d">official journal of the American Society for Histocompatibility and Immunogenetics (ASHI)</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000456578</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:487-492</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.humimm.2019.03.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2019</subfield><subfield code="e">7</subfield><subfield code="h">487-492</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.3972797 |